AR124744A1 - AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS) - Google Patents

AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)

Info

Publication number
AR124744A1
AR124744A1 ARP220100346A ARP220100346A AR124744A1 AR 124744 A1 AR124744 A1 AR 124744A1 AR P220100346 A ARP220100346 A AR P220100346A AR P220100346 A ARP220100346 A AR P220100346A AR 124744 A1 AR124744 A1 AR 124744A1
Authority
AR
Argentina
Prior art keywords
seq
agent
genome
cov
age
Prior art date
Application number
ARP220100346A
Other languages
Spanish (es)
Inventor
Olga Vadimovna Zubkova
Tatiana Andreevna Ozharovskaia
Inna Vadimovna Dolzhikova
Olga Popova
Dmitrii Viktorovich Shchebliakov
Daria Mikhailovna Grousova
Alina Shahmirovna Dzharullaeva
Amir Ildarovich Tukhvatulin
Natalia Mikhailovna Tukhvatulina
Dmitrii Nikolaevich Shcherbinin
Ilias Bulatovich Esmagambetov
Elizaveta Alexsandrovna Tokarskaya
Andrei Gennadevich Botikov
Alina Sergeevna Eroxova
Fatima Magomedovna Izhaeva
Natalia Anatolevna Nikitenko
Nadezhda Leonidovna Lubenets
Aleksandr Sergeevich Semikhin
Sergei Vladimirovich Borisevich
Boris Savelievich Naroditsky
Denis Yuryevich Logunov
Aleksandr Leonidovich Gintsburg
Vladimir Aleksandrovich Chernetsov
Evgenii Vladimirovich Kriukov
Vladimir Fedorovich Babira
Dmitrii Anatolevich Kutaev
Svetlana Iakovlevna Loginova
Original Assignee
Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft filed Critical Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft
Publication of AR124744A1 publication Critical patent/AR124744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se relaciona con el campo de biotecnología, inmunología y virología. Un agente para uso en la inducción de inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2 en sujetos mayores de 60 años de edad y/o con enfermedades crónicas es divulgado, conteniendo dicho agente un componente 1, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus humano de serotipo 26 con sitios E1 y E3 eliminados del genoma, y el sitio ORF6-Ad26 está sustituido por ORF6-Ad5 con un casete de expresión integrado seleccionado entre SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, y/o que contiene un componente 2, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus humano de serotipo 5 con sitios E1 y E3 eliminados del genoma con un casete de expresión integrado seleccionado entre SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3. Además, se divulga un agente para uso en la inducción de inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2 en sujetos mayores de 60 años y/o que tengan enfermedades crónicas, conteniendo dicho agente un componente 1, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus humano serotipo 26 con sitios E1 y E3 eliminados del genoma, y el sitio ORF6-Ad26 está sustituido por ORF6-Ad5 con un casete de expresión integrado seleccionado entre SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, y que también contiene un componente 2, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus de simio de serotipo 25 con sitios E1 y E3 eliminados del genoma con un casete de expresión integrado seleccionado entre SEQ ID Nº 4, SEQ ID Nº 2, SEQ ID Nº 3, o que contiene solo el componente 2. Además, se divulga un agente para uso en la inducción de inmunidad específica contra el síndrome respiratorio agudo severo SARS-CoV-2 en sujetos mayores de 60 años de edad y/o que tienen enfermedades crónicas, conteniendo dicho agente un componente 1, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus de simio de serotipo 25 con sitios E1 y E3 eliminados del genoma con un casete de expresión integrado seleccionado entre SEQ ID Nº 4, SEQ ID Nº 2, SEQ ID Nº 3, y que también contiene un componente 2, que es un agente en forma de vector de expresión basado en el genoma de una cepa recombinante de adenovirus humano de serotipo 5 con sitios E1 y E3 eliminados del genoma con el casete de expresión integrado seleccionado de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3. Las invenciones proporcionan inducción eficaz de la respuesta inmune contra el virus SARS-CoV-2 en sujetos mayores de 60 años de edad y que también tienen enfermedades crónicas.The invention relates to the field of biotechnology, immunology and virology. An agent for use in inducing specific immunity against the SARS-CoV-2 severe acute respiratory syndrome virus in subjects over 60 years of age and/or with chronic diseases is disclosed, said agent containing component 1, which is a agent in the form of an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the ORF6-Ad26 site is replaced by ORF6-Ad5 with an integrated expression cassette selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and/or containing a component 2, which is an agent in the form of an expression vector based on the genome of a recombinant strain of human adenovirus serotype 5 with sites E1 and E3 deleted from the genome with an integrated expression cassette selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3. Furthermore, an agent for use in inducing specific immunity against acute respiratory syndrome virus is disclosed. severe SARS-CoV-2 in subjects over 60 years of age and/or who have chronic diseases, said agent containing component 1, which is an agent in the form of an expression vector based on the genome of a recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the ORF6-Ad26 site is replaced by ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and also containing a component 2, which is an agent in the form of an expression vector based on the genome of a serotype 25 recombinant strain of simian adenovirus with E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID No. 4, SEQ ID No. 2, SEQ ID No. 3, or containing only component 2. Furthermore, an agent is disclosed for use in inducing specific immunity against severe acute respiratory syndrome SARS-CoV-2 in subjects over 60 years of age and /or who have chronic diseases, said agent containing a component 1, which is an agent in the form of an expression vector based on the genome of a recombinant strain of serotype 25 simian adenovirus with E1 and E3 sites deleted from the genome with a cassette integrated expression agent selected from SEQ ID No. 4, SEQ ID No. 2, SEQ ID No. 3, and which also contains a component 2, which is an agent in the form of an expression vector based on the genome of a recombinant strain of human adenovirus of serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3. The inventions provide efficient induction of immune response against SARS-CoV-2 virus in subjects older than 60 years of age and who also have chronic diseases.

ARP220100346A 2021-02-21 2022-02-18 AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS) AR124744A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021104430A RU2744442C1 (en) 2021-02-21 2021-02-21 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)

Publications (1)

Publication Number Publication Date
AR124744A1 true AR124744A1 (en) 2023-05-03

Family

ID=74857783

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100346A AR124744A1 (en) 2021-02-21 2022-02-18 AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)

Country Status (3)

Country Link
AR (1) AR124744A1 (en)
RU (1) RU2744442C1 (en)
WO (1) WO2022177465A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974950B (en) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 Adenovirus vector vaccine for preventing SARS-CoV-2 infection
CN111217917B (en) * 2020-02-26 2020-10-23 康希诺生物股份公司 Novel coronavirus SARS-CoV-2 vaccine and preparation method thereof
RU2738081C1 (en) * 2020-10-14 2020-12-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере зашиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Peptide immunogens and a vaccine composition against coronavirus infection covid-19 using peptide immunogens
RU2743593C1 (en) * 2020-12-09 2021-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Peptide immunogens and vaccine composition against covid-19 with the use of peptide immunogens
RU2743595C1 (en) * 2020-12-09 2021-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Vaccine composition against covid-19

Also Published As

Publication number Publication date
WO2022177465A1 (en) 2022-08-25
RU2744442C1 (en) 2021-03-09

Similar Documents

Publication Publication Date Title
AR121931A1 (en) IMMUNOBIOLOGICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)
CL2018003769A1 (en) A strain of the attenuated virus of African swine fever that rationally protects against parental virus infection Georgia 2007 isolated.
JP2016539946A5 (en)
CO2020002283A2 (en) Factor viii (fviii) gene therapy methods
AR126626A1 (en) AGENT TO INDUCE SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 IN LIQUID FORM (VARIANTS)
AR093185A1 (en) PRRS VIRUS (SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME) THAT INDUCES TYPE I INTERFER IN SUSCEPTIBLE CELLS
PE20090653A1 (en) IMMUNOGENIC FORMULATION, BECAUSE IT INCLUDES AN ATTENUATED RECOMBINANT STRAIN OF MYCOBACTERIUM, PREFERENTIALLY THE RECOMBINANT STRAIN BACILO DE CALMETTE AND GUERIN (BCG), WHICH EXPRESSES AT LEAST ONE PROTEIN OR RESPIRATORY IMMUNOGENIC FRAGMENT OF THE VIRUS
BR0316291A (en) Hcv vaccine, methods of preventing or treating an hcv infection in a mammal and vaccinating an individual, and using a hcv vaccine
AR124744A1 (en) AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
Kasimov et al. ANALYSIS OF THE EFFECTIVENESS OF COVID-19 VACCINOPROPHYLAXIS ON THE EXAMPLE OF THE CITY OF TASHKENT
AR124745A1 (en) AGENT FOR USE IN THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 FOR POPULATION REVACCINATION (VARIANTS)
ZA202203564B (en) The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants)
AR124461A1 (en) AAV5-BASED VACCINE FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARS-CoV-2 AND/OR THE PREVENTION OF SARS-CoV-2-RELATED CORONAVIRUS INFECTION
BR112022004778A2 (en) AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE
BR112022003581A2 (en) EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2
BRPI0414073A (en) method for inducing an immune response against rotavirus infection from a rotavirus serotype, and use of an attenuated rotavirus strain of a serotype
Best et al. IFN-lambda: The key to norovirus’s secret hideaway
ZA202203565B (en) The use of the agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 for revaccination of population (variants)
CO2022019251A2 (en) Compositions and methods useful for the prevention and/or treatment of diseases in mammals
AR125270A1 (en) PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)
AR124746A1 (en) AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 IN CHILDREN
ZA202202321B (en) Pharmaceutical agent for inducing specific immunity against sars-cov-2
AR124040A1 (en) IMMUNOGENIC FORMULATION CONTAINING A MODIFIED BCG STRAIN THAT EXPRESSES AN ANDESVIRUS (ANDV) PROTEIN USEFUL FOR PREVENTING AND TREATING HANTA-ANDV VIRUS INFECTIONS
Butenko et al. Vaccination of the flu in the season 2016-2017